Pelthos Therapeutics Inc. (PTHS)

NYSEAMERICAN: PTHS · Real-Time Price · USD

24.97

+0.20 (0.81%)

At close: Apr 28, 2026, 4:00 PM EDT

24.97

0.00 (0.00%)

After-hours: Apr 28, 2026, 8:00 PM EDT

0.81% (1D)

Market Cap	83.79M
Revenue (ttm)	16.80M
Net Income (ttm)	-43.32M
Shares Out	3.36M
EPS (ttm)	-23.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	45,715
Open	24.80
Previous Close	24.77
Day's Range	24.77 - 26.20
52-Week Range	9.00 - 54.29
Beta	3.99
Analysts	Strong Buy
Price Target	54.17 (+116.94%)
Earnings Date	May 13, 2026

About PTHS

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestati... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2002

Employees 92

Stock Exchange NYSEAMERICAN

Ticker Symbol PTHS

Website https://pelthos.com

Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for PTHS stock is "Strong Buy." The 12-month stock price target is $54.17, which is an increase of 116.94% from the latest price.

Price Target

$54.17

(116.94% upside)

Analyst Consensus: Strong Buy

Stock Forecasts

News

Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain

First clinical trial conducted in human subjects to evaluate CT2000 for the treatment of both acute ocular pain and chronic ocular surface pain commonly associated with dry eye disease

4 weeks ago - GlobeNewsWire

Pelthos Therapeutics Transcript: The 38th Annual Roth Conference

Pelthos has rapidly grown ZELSUVMI prescriptions and revenue, with strong payer coverage and a robust cash position. Upcoming launches of Xepi and Xeglyze will leverage existing sales channels, while patent protection and proprietary manufacturing support long-term growth.

5 weeks ago - Transcripts

Pelthos Therapeutics Earnings Call Transcript: Q4 2025

Q4 2025 saw strong revenue growth and reduced losses, driven by ZELSUVMI's rapid uptake and expanded coverage. Two FDA-approved product acquisitions and new financing position the company for continued growth and expected profitability by year-end 2026.

5 weeks ago - Transcripts

Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results

ZELSUVMI ™ net product revenue grew 28% Quarter over Quarter to $9.1 million, bringing total ZELSUVMI net product revenue to $16.2 million, for the period from the launch in July 2025 through December...

5 weeks ago - GlobeNewsWire

Pelthos Therapeutics to Present at 38th Annual ROTH Conference

DURHAM, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet pat...

6 weeks ago - GlobeNewsWire

Pelthos Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Recent commercial launch of ZELSUVMI for pediatric molluscum contagiosum has exceeded expectations, driving strong revenue growth and rapid prescriber adoption. Portfolio expansion with Xepi and Xeglyze leverages existing infrastructure, while robust patent protection and financial position support future growth.

2 months ago - Transcripts

Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics

FARMINGTON, Conn.--(BUSINESS WIRE)--Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon”) (the “Company”), an affiliate of Monroe Capital, today announced it has provided a $50 million ven...

Other symbols: HRZN

3 months ago - Business Wire

Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance

The minimally dilutive funding will accelerate Pelthos' highly successful commercialization efforts for its lead product, ZELSUVMI™ (berdazimer) topical gel, 10.3% for the treatment of molluscum conta...

3 months ago - GlobeNewsWire

Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice

DURHAM, N.C., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet pati...

4 months ago - GlobeNewsWire

Pelthos Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

A major payer win expands access for Zelsuvmi, driving rapid prescription growth and supporting a salesforce expansion. Zelsuvmi, the only FDA-approved at-home molluscum treatment, and newly acquired Xepi for impetigo, both target large pediatric markets with strong market access and IP protection.

5 months ago - Transcripts

Pelthos Therapeutics Earnings Call Transcript: Q3 2025

Q3 2025 saw a strong ZELSUVMI launch, generating $7.1M in revenue and rapid prescription growth, supported by expanded sales force and new financing. The company expects to reach cash flow break-even by end of 2026 and projects continued revenue growth, with Xepi launch planned for late 2026.